Ebola in great apes – current knowledge, possibilities for vaccination, and implications for conservation and human health by Leendertz, Siv Aina J. et al.
Kent Academic Repository
Full text document (pdf)
Copyright & reuse
Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all
content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions 
for further reuse of content should be sought from the publisher, author or other copyright holder. 
Versions of research
The version in the Kent Academic Repository may differ from the final published version. 
Users are advised to check http://kar.kent.ac.uk for the status of the paper. Users should always cite the 
published version of record.
Enquiries
For any further enquiries regarding the licence status of this document, please contact: 
researchsupport@kent.ac.uk
If you believe this document infringes copyright then please contact the KAR admin team with the take-down 
information provided at http://kar.kent.ac.uk/contact.html
Citation for published version
Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder,
Mary K. and Humle, Tatyana and Leendertz, Fabian H.  (2016) Ebola in great apes – current knowledge,
possibilities for vaccination, and implications for conservation and human health.   Mammal Review
.    ISSN 0305-1838.
DOI
https://doi.org/10.1111/mam.12082




Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder, Mary K. and Humle, 
Tatyana and Leendertz, Fabian H. (2016) Ebola in great apes ± current knowledge, possibilities for vaccination, and 





EBOLA IN GREAT APES - CURRENT KNOWLEDGE, POSSIBILITIES FOR 




1. Ebola virus disease (EVD) is a threat to human health and the survival of African great apes. The 
disease has led to major population declines of chimpanzees and gorillas, and infected great apes play 
an important role as sources of human EVD outbreaks. The threat posed by EVD raises the question 
whether vaccination of wild apes is a possible strategy to reduce the occurence and impact of this 
disease. 
2. This article reviews the current knowledge about EVD in great apes and emphasizes the link 
between ape and human outbreaks. It discusses the need for control strategies such as vaccination and 
describes aspects of primate behavior, virus biology, vaccine composition, and vaccination principles 
that are necessary to consider when making management decisions about great ape vaccination. 
Finally, it identifies gaps in the understanding of Ebola ecology and highlights surveillance and 
research that can aid the survival of great apes and reduce human exposure to Ebola virus. 
3. The unpredictable emergence of Ebola viruses and the severe impact of EVD call for efficient 
monitoring and ultimately control of Ebola. This article provides a platform for further 
interdiciplinary discussions to decide on optimal management solutions regarding vaccination of 
great apes against Ebola.   
 
KEY WORDS: conservation, Ebola, global health, vaccination, wild great apes 
RUNNING HEAD: Ebola in great apes 
WORD COUNT: 9945 
Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder, Mary K. and Humle, 
Tatyana and Leendertz, Fabian H. (2016) Ebola in great apes ± current knowledge, possibilities for vaccination, and 







Ebola virus disease (EVD) is an acute, severe and lethal disease of particular concern for humans, 
chimpanzees, and gorillas (Karesh & Reed 2005, Feldmann & Geisbert 2011). The disease is caused 
by viruses of the Ebola genus, belonging to the virus family Filoviridae (Kuhn et al. 2010). The Ebola 
genus comprises five distinct species, although they are generally referred to as the Ebola virus or 
simply Ebola. Since the first Ebola virus was discovered in 1976, Ebola viruses (EVs) have 
sporadically re-emerged from an unknown reservoir and caused more than 20 human outbreaks across 
Africa (Anonymous 2015a). The epidemic that started in West Africa in December 2013 has lasted 
for more than two years and claimed more than 11,000 lives (Anonymous 2015b). 
EVD is also considered a major threat to the survival of African great apes, all of which are currently 
listed as Endangered or Critically Endangered (Anonymous 2016a). The disease in apes is also of 
concern for human health as there is a clear link between Ebola-infected apes and human EVD 
outbreaks. For all eight human outbreaks in Gabon and the Republic of Congo (ROC) which have 
occurred in the last 25 years, there is epidemiological evidence (and in three of these outbreaks also 
laboratory evidence) that they were initiated by contact to infected bush meat from gorillas (Gorilla 
gorilla gorilla) or chimpanzees (Pan troglodytes troglodytes) (Georges et al. 1999, Rouquet et al. 
2005), hence hunting or scavenging of wild great apes is a major risk factor. Bats, monkeys, and 
perhaps other wildlife are also possibly able to infect humans; however, the true reservoir(s) and 
natural circulation of EVs still remain unidentified (Lahm et al. 2007, Leendertz et al. 2015, Maganga 
et al. 2014, Mari Saez et al. 2015, Olival & Hayman 2014, Olson et al. 2012). This makes prediction, 
surveillance and control of EVD challenging.  
The threats posed by EVD, raise the question of whether vaccination of wild great apes would be a 
future option to help mitigate the effect of EVD on ape populations and protect human health. 
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Although no outbreak has been confirmed in apes since 2005, the unpredictable pattern of virus 
emergence and the severe impact of outbreaks mean that there is a true concern of future occurrences.  
This article provides an overview of what is known about EVD in great apes, and highlights 
surveillance and research that can aid the survival of wild great apes and reduce human exposure to 
Ebola virus. Moreover, it describes aspects of primate behavior, Ebola virus biology and ecology, 
vaccine composition, and vaccination principles that are essential to know when considering 
vaccination of great apes. This article provides a platform for further interdiciplinary discussions to 
decide on optimal management solutions regarding protection of wild great apes against Ebola.   
 
EBOLA VIRUS DISEASE 
Four separate species of EVs cause EVD in Africa; Zaire EV (ZEBOV), Sudan EV (SEBOV), Cote 
G¶,YRLUH(9TFEBOV) and Bundibugyo EV (BEBOV), of which ZEBOV and TFEBOV have so far 
been detected in great apes (Leroy et al. 2004, Rouquet et al. 2005, Wittmann et al. 2007, Kuhn et 
al. 2010). The genetic diversity of these Ebola species represents a hurdle for vaccine development 
since a vaccine working against one species might not protect against another (i.e. lack of cross 
reaction) (Feldmann & Geisbert 2011). A fifth member of the Ebola genus (Reston Ebola virus, 
REBOV) exists in Asia; however, this virus is not thought to be lethal to humans, hence the EVD 
pathogenesis described below does not apply to this virus species. There have been no reported cases 
of EVD in orang-utans.  
The biological aspects of the EVD disease process are similar in humans and apes (Kuhn 2008). EVs 
are highly infectious and enter the body through contact with mucus membranes, eyes, and broken 
skin. After an incubation period of 2-21 days, the infected individual develops symptoms which 
include fever, vomiting, diarrhoea, internal and sometimes external bleeding. There are few 
observations of wild apes that have presumably been suffering from EVD, but signs of abdominal 
pain, lethargy, poor appetite, diarrhoea and emDFLDWLRQRUVLPSO\³DEQRUPDOEHKDYLRXU´KDYHEHHQ
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noted in great apes, and bleeding from the nostrils has been observed among other non-human 
primates (NHPs) (Formenty et al. 1999, Georges et al. 1999, Lahm et al. 2007). Other individuals 
can get infected through contact with the body or body fluids from a sick or dead member of the 
social group (Warren & Williamson 2004). It is debated how infection can spread through ape 
populations over large geographical areas and there are two main theories. The first theory proposes 
that the spread occurs solely by group-to-group infection after a single or few introductions of the 
virus from the original reservoir or other infected animals into an uninfected ape population. Such 
spread could occur via direct contact such as intergroup encounters, extra-community copulation, and 
emigration of females (including infected gorilla females leaving the group after death of the 
silverback), or indirectly, via sharing of feeding sites or home range (Vigilant et al. 2001, Bermejo 
2004, Bradley et al. 2004). EV has been isolated in semen of infected human males many months 
after infection (Chughtai et al. 2016) indicating that surviving male apes could initiate new infection 
chains if mating occurs within the infectious period. The potential for group-to-group spread in apes 
depends on several factors including the incubation time of the specific individual (or longevity of 
infectious semen), travel distance and ape density (Walsh et al. 2007,  Walsh et al. 2009, Ryan et al. 
2013). The sociality of African apes, including the natural fission-fusion social system of 
chimpanzees (Lehmann & Boesch 2004) will also influence the spread of virus in a positive or 
negative way, depending on the contact pattern and which individuals are infected. 
The second theory of how infection can spread over large areas proposes that outbreaks occur mainly 
as a direct consequence of repeated spill-over from a so far unidentified natural host into 
geographically separated ape social groups. The outbreak distribution is consequently defined by the 
dispersal and movements of the reservoir host itself rather than the apes (Leroy et al. 2004). However, 
these two theories are not mutually exclusive, as it is possible that both these modes of transmission 
are important, and that one or the other can predominate at times or sites depending on the underlying 
IDFWRUVWKDWWULJJHURUVXVWDLQWKHRXWEUHDNV,QDQ\FDVH(EROD¶VWUHPHQGRXVDELOLW\WRVSUHDGUDSLGO\
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once it has emerged is illustrated by the recent human outbreak in West Africa, which started with 
one infected child and subsequently included nearly 30,000 people (Mari Saez et al. 2015, 
Anonymous 2015c).  
Experimental infections show that deaths in NHPs occur within a similar time frame as in humans 
(ca.8-10 days after onset of symptoms for ZEBOV and ca.12-14 days for TFEBOV) (Geisbert et al. 
2009). Although the mortality rate can be extremely high (up to 88% in humans and possibly higher 
in great apes infected with ZEBOV [Bermejo et al. 2006, Anonymous 2015c]), it is evident that 
recovery and survival after infection is possible. Antibodies to Ebola virus have been detected in 
blood from humans, wild-born chimpanzees and other primates and in the feces from wild-living 
gorillas, proving that some individuals exposed to the virus can mount an immune response and 
recover after infection  (Leroy et al. 2004, Lahm et al. 2007, Reed et al. 2014). Survival of individuals 
in great ape groups whose other members have died of Ebola also suggest that recovery is possible 
(Formenty et al. 1999, Bermejo et al. 2006); however, without laboratory testing of samples, it is not 
possible to ascertain whether these individuals were in fact infected or managed to escape exposure. 
The infectious, acute and often lethal nature of Ebola shows, however, that great apes are unlikely to 
be able to indefinitely sustain an infection chain.  
An outbreak stops naturally when no more susceptible individuals come in contact with infectious 
apes (dead or alive) or infectious materials. Leroy and colleagues (2004) reported carcasses remaining 
infectious in the rainforest for 3-4 days; it remains however uncertain how long EV survives under 
different environmental conditions (Anonymous 2014a).  
 
OCCURENCE AND IMPACT OF EVD IN GREAT APES  
EVD in great apes was first recognized nearly twenty years after the Ebola virus was discovered in 
humans (Pigott et al. 2014).  Ape outbreaks have mainly been detected in Central Africa whereas 
human outbreaks have occurred across tropical Africa (Figure 1). 
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TFEBOV was the first ape-associated Ebola species to be discovered when 12 habituated 
chimpanzees (Pan troglodytes verus LQ WKH7Dʀ1DWLRQDO3DUN&{WHG¶,YRLUHGLHGRUGLVDSSHDUHG
within a few weeks in November 1994 (Formenty et al. 1999).  Ebola was confirmed by 
immunohistology staining of virus in carcass samples and by virus isolation from a researcher who 
contracted EVD after exposure to the carcass. Mortality rate in the chimpanzee group was estimated 
to ca. 25%, similar to what has been observed in outbreaks of human BEBOV (an Ebola species not 
detected in apes) (Towner et al. 2008). There was no further human-to-human transmission in this 
case and TFEBOV has not been detected again in Africa.  
The ZEBOV species has had a much more significant impact on great apes. Outbreaks have occurred 
in North Eastern Gabon and ROC in two clusters: first in the mid-1990s and then in the first five years 
of this century. Surveillance of wild great apes is challenging and does not cover all wild populations 
hence outbreaks could also have occurred undetected at other times. Most of what is known about the 
outbreaks in apes in North Eastern Gabon in the mid-1990s emanated from investigations of three 
human outbreaks that occurred at that time (Georges et al. 1999). In November 1994, there were 
concurrent reports of wildlife deaths among the local gorilla and chimpanzee populations when the 
first human cases appeared in gold mining camps in the Minkebé forest area. About a year later, 
butchering a dead chimpanzee found ca. 40 km further south initiated a second human outbreak. The 
third human outbreak started yet another 160 km further south six months later with the death of two 
hunters, of which one was said to have killed several mangabeys in the time before he got sick. Dead 
chimpanzees and gorillas were encountered on several occasions during and after these outbreak 
years, indicating that EVD was affecting the apes for a long time (Georges et al. 1999, Lahm et al. 
2007). From these dead apes, a skin sample tested positive in Ebola immunohistology staining. 
Wildlife surveys carried out in Minkebé and Mwagne forest blocks before and after these outbreak 
years showed a dramatic reduction (90-98%) in the gorilla and chimpanzee populations that could 
have been caused by a highly lethal, rapidly spreading disease like EVD (Huijbregts et al. 2003, 
Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder, Mary K. and Humle, 
Tatyana and Leendertz, Fabian H. (2016) Ebola in great apes ± current knowledge, possibilities for vaccination, and 





Maisels et al. 2004, Lahm et al. 2007). In comparison, the mortality in humans exposed to the same 
virus was 59-75% in the concurrent outbreaks. The relatively lower human mortality is possibly due 
to hospital care of infected people rather than a higher biological disease resistance. 
A surveillance network was subsequently set up in North Eastern Gabon and ROC due to the 
association between human EVD outbreaks, the regularity of human contact with apes and/or ape 
meat in these countries and the decline of great ape populations. This network, which also included 
monitoring and sampling of a range of wildlife carcasses, revealed that five human EVD outbreaks 
that occurred between October 2001 and May 2005 resulted from contact to infected carcasses, 
mainly gorillas and chimpanzees (Leroy et al. 2004, Rouquet et al. 2005, Nkoghe et al. 2011). Ebola 
positive ape carcasses were found in several forest areas including Lossi and Odzala National Parks, 
ROC, where population losses exceeding 90% were observed in habituated gorillas (Bermejo et al. 
2006). In Lossi alone Ebola was estimated to have killed 5,000 individuals.  Ebola is believed to have 
caused ape deaths in Odzala until at least 2007 (Caillaud et al. 2006, Cameron et al. 2016), however, 
since 2005, no further cases of EVD in African apes have been confirmed.  A human EVD outbreak 
in Boende, DRC, in 2014 might have been linked to contact with a primate carcass (species 
unidentified) (Maganga et al. 2014), however, no samples have been obtained for testing and the link 
remains speculative. The human 2013-2016 EVD epidemic in West Africa is not believed to be 
associated with deaths of great apes or other primates, but is rather thought to be the consequence of 
DFKLOG¶VDFFLGHQWDOFRQWDFWZLWKDODUJHFRORQ\RILQVHFWLYRURXVEDWV0DUL6DH]et al. 2014). The area 
where the epidemic started harbours few primates, no case of dead apes has been reported and recent 
surveys indicate no decline in primate populations compared with surveys conducted prior to the 
outbreak. 
In summary, EVD has likely killed thousands of gorillas and chimpanzees in the central African 
UDLQIRUHVWVZKHUHWKHPDMRULW\RIWKHZRUOG¶VUHPDLQLQJJUHDWDSHSRSXODWLRQVUHVLGH9RJHO006, 
Hopkin 2007).  Because of these losses, the IUCN upgraded the western lowland gorilla to critically 
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endangered in 2007 (Walsh et al. 2007). Carcass samples and precise assessments of wild great ape 
population sizes are challenging to obtain, making it difficult to estimate the true impact of Ebola on 
great apes. There is, however, no reason to doubt that EVD can severely affect great ape populations; 
and in fact, until the start of the recent epidemic in West Africa, the number of apes estimated to have 
succumbed to Ebola was far greater than the total number of people (ca.1500) who died from the 
same virus in all known human outbreaks (Anonymous 2015b).  
 
WHERE AND HOW DO THE APES GET INFECTED WITH EBOLA? 
,WLVHYLGHQWIURPWKHGLVHDVH¶VUDSLGVSUHDGDQGKLJKPRUWDOLW\LQJUHDWDSHVWKDWWKHVHSULPDWHVDUH
neither natural, asymptomatic carriers of the virus nor able to sustain the infection indefinitely, which 
are both important criteria for a reservoir host (Olival & Hayman 2014). The apes are rather so-called 
µDFFLGHQWDOKRVWV¶ZKRDFWDVDVRXUFHRILQIHFWLRQIRUKXPDQRXWEUHDNVZKHQWKH\WKHPVHOYHVDUH
infected from another host(s) sharing the same habitat. Numerous carcasses of other animals found 
in the Gabon and ROC forests between 1994 and 2005 indicate that many species may be susceptible 
to EV, although the virus has only been isolated from gorillas, chimpanzees and a duiker 
(Cephalophus sp.) despite intensive testing of wildlife carcasses in outbreak areas for decades (Leroy 
et al. 2004, Lahm et al. 2007, Wittmann et al. 2007). Laboratory analyses of samples from certain 
fruit eating and insect eating bats indicate that these bats were able to host, possibly spread and indeed 
survive infection; however, the virus itself has never been isolated from these hosts and more research 
is necessary to confirm that the virus is circulating primarily in any of these species or if yet another 
host represents the true reservoir (Olival & Hayman 2014, Leendertz et al. 2015).   Until the natural 
history and ecology of Ebola are more fully characterized, it is only possible to speculate about if and 
how apes (and humans) get infected from bats or other species (Viana et al. 2014). Apes are not 
known to hunt bats, but could potentially come in direct contact with fruit bats roosting in trees where 
apes feed, or with insectivorous bats roosting in tree holes where the apes search for honey, insects 
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or water (Nishida 2010). Alternatively they could get infected via excretions from any kind of bat or 
other animal when ingesting contaminated food via feces, urine or saliva, although such excretion of 
EV in naturally infected bats is yet to be confirmed (Olival & Hayman 2014). Direct contact with 
other infected hosts is another possible infection route, including hunting of monkeys or other prey 
that might be infected and/or during inspections of infected carcasses (Boesch & Boesch-Achermann 
2000, Karesh et al. 2012).   In the chimpanzee outbreak in CôWH G¶,YRLUH, red colobus monkey 
predation was considered a risk factor (Formenty et al. 1999), but was not confirmed as a transmission 
route. 
The uncertainties of Ebola ecology make predicting outbreaks in wildlife (and humans when no 
previous wildlife outbreak is detected) nearly impossible and without further data most of the tropical 
belt of Africa is considered a risk area for Ebola emergence (Pigott et al. 2014). This has implications 
for outbreak preparedness in humans and wildlife alike. What is clear, however, is that apes are 
intermittently exposed to EVs in their natural environment, which means that we might not be able 
to remove, or prevent exposure to, the source of infection. This highlights the need for considering 
strategies to prevent  EV infection  of great apes, and to also break the link between them and human 
EVD outbreaks (Feldmann & Geisbert 2011). 
 
THE BENEFITS AND POSSIBILITIES OF PREVENTING OR REDUCING SPREAD OF 
EBOLA WITHIN APE POPULATIONS 
Considering the severe reduction in population number and dissemination of groups that follows EVD 
outbreaks in great apes it is highly questionable if leaving this disease to be regulated by nature itself 
is a viable option. Demographic structure changes (for example increased frequency of emigration to 
start new breeding groups) of populations after severe declines can indeed occur to favour population 
growth (Genton et al. 2012, Genton et al. 2014, Reed et al. 2014), however, in the case of repeated 
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outbreaks and added pressure from other infectious diseases, bushmeat hunting and deforestation 
these recovery strategies might not be sufficient to prevent extinction (Leendertz et al. 2006, Morgan 
& Sanz 2007, Kondgen et al. 2008, N'Goran et al. 2012).  Apes have a relatively long generation time 
(Anonymous 2014a) which means that an outbreak of a disease with high mortality rate such as EVD 
requires a very long recovery time for affected populations; some calculated that it would take the 
affected gorilla population in Lossi more than 130 years to recover to initial population numbers 
(Ryan & Walsh 2011). In addition, fragmentation of populations due to mortality also has a negative 
impact on the genetic diversity of the populations, which could exacerbate extinction risk especially 
when populations are reduced in size. Therefore, it is clear that efficient strategies to reduce the impact 
on EVD in wild population will be beneficial for conservation. Further, prevention or reduction of 
infectious diseases in wildlife, including preservation of natural ecosystem integrity and biodiversity, 
will ultimately have a positive impact on human health (Rabinowitz et al. 2013).  It should however 
be noted that not all human EVD originated from infected great apes, hence such strategies will not 
prevent human exposure to EVs from other wildlife sources (Anonymous 2015a). 
The questions that arise when any wildlife is concerned, is if any intervention in a natural ecosystem 
is justified.  The benefits of any intervention must be assessed in conjunction with the potential 
negative impacts (Fedigan 2010, Gruen et al. 2013). Nearly all great ape populations have been, and 
continue to be, impacted by human influence, such that apart from some of the protected areas, the 
PDMRULW\RIWKH$IULFDQIRUHVWVFDQQRORQJHUEHFRQVLGHUHGµQDWXUDO¶/DXUDQFH+RFNLQJVet al. 
2015).  Preserving protected species is required by law and there should be an additional moral 
responsibility to preserve endangered species, and further, human-induced environmental changes 
such as deforestation and urbanisation may exacerbate the likelihood of EV emergence (Waldman 
2015). Hence it seems rational to focus upon how to protect the remaining wild great apes from a 
disease that are incompatible with survival of the species should outbreaks continue to occur, rather 
than discussing if human intervention is justified. Hypothetical possibilities to prevent the spread of 
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Ebola within ape populations exist, however the questions of which strategy or strategies would be 
feasible and efficient, despite limited knowledge about the natural ecology of these viruses and their 
unpredictable emergence, remains.  
In human EVD outbreaks, isolation of infected cases remains an important control strategy 
(Anonymous 2015d). Protection of the great apes cannot rely upon similar isolation strategies, 
although it might naturally occur to some degree as apes sometimes temporarily leave the rest of the 
social group when experiencing signs of disease (Boesch & Boesch-Achermann 2000). It is evident 
that some isolated groups of chimpanzees and gorillas continued to thrive in one instance only 20km 
from an outbreak area (Lahm et al. 2007), hence geographical separation could theoretically provide 
protection. However, attempting to isolate social groups by cutting corridors in the forest in order to 
stop spread of infected apes is unlikely to be feasible, desirable or efficient for various reasons. Firstly, 
clearing of larger geographical areas in dense and remote rainforest areas is laboursome and in 
conflict with forest preservation, and as apes are able to cross large open areas the effort might not 
even be worthwhile (Haurez et al. 2013). Further, should separation be successful it might create 
stress for the apes due to man-made disturbance and change in their territory, and in longer term 
compromise the population genetic viability. And finally, the virus could be introduced to other parts 
of the forest by reservoir hosts not restricted by human-made barriers, which make attempts to 
geographically separate ape groups to avoid spread of infection redundant.  
Preliminary results regarding experimental post-exposure treatments based on protective antibodies 
(e.g. ZMapp) are encouraging; however, patients require additional intensive care, hence such 
medication is unlikely to be effective in controlling EVD outbreaks in wild apes, even when 
habituated. Vaccination, i.e. administration of preventative medication which stimulates an immune 
response that will protect the individuals against natural exposure to the virus, could possibly be the 
most promising control strategy in great apes. Indeed, the prospect of safe and efficient Ebola 
vaccines in the near future invites a discussion about their use in wild populations of great apes (Marzi 
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& Feldmann 2014). There are significant ethical issues when considering the vaccination of wild 
great apes, though it should be noted that in humans the prospective use of vaccines is also not without 
its own ethical and practical concerns (Cohen & Kupferschmidt 2014, Lee et al. 2015). 
It is not the first time that vaccines have been used in wild apes (Ryan & Walsh 2011). For example, 
small scale vaccination has been done in habituated (or reintroduced) populations for diseases like 
measles, poliomyelitis, tetanus, and anthrax (Goodall 1986, Hastings et al. 1991, Ryan & Walsh 
2011).  Vaccinations were done through distance darting, injections when other interventions were 
undertaken under general anaesthesia, or in the case of chimpanzee poliomyelitis in the mid-1960s, 
through feeding of bananas; an acceptable practice at the time. 
 
THE PROSPECT OF VACCINATING WILD GREAT APES AGAINST EBOLA 
Implementation of great ape vaccination programs seems superficially straightforward, since humans 
and great apes are genetically and physiologically similar and exhibit similar immunological reactions 
to vaccines. However, accessibility of great apes due to their elusive nature and occurrence in remote 
habitats, limits the choice of vaccine(s) and call for well-considered vaccination strategies. A 
thorough understanding of EVD, the great apes natural behavior, and the vaccines that might become 
available in the future is required for discussing and deciding on appropriate vaccination strategies. 
 
CURRENT VACCINE CANDIDATES 
In the last decades, a number of vaccine types have been tested in suitable animal models including 
non-human primates and some have subsequently advanced into human clinical trials (Marzi & 
Feldmann 2014, Falzarano 2016).  Regardless if a vaccine is intended for human or great ape use, it 
is extremely important to assure its safety; crisis situations should not bypass the need to establish a 
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YDFFLQH¶VULVN-benefit profile and to address both real and perceived safety concerns (Lee et al. 2015, 
Rougeron et al. 2015). 
To understand the possible use and limitations of vaccines in great apes (and humans), it is essential 
to understand that vaccine candidates differ in their composition; defining so-called different vaccine 
platforms (Marzi & Feldmann 2014).  The composition of the vaccine determines which type and 
degree of immune reaction it stimulates, and if a vaccine needs to be injected rather than administered 
via other routes to induce sufficient protection from infection. Subsequently, this decides which type 
and how many interventions are necessary on the individual or population level to induce protection 
and how long this protection lasts. 
Several Ebola vaccine candidates are vector-based vaccines that consist of some type of relatively 
benign virus that has been genetically modified to display Ebola specific antigens on the surface. In 
this way, the vector virus will present itself as Ebola virus to the vaccinated host and activate an 
appropriate immune response as long as it is viable. Such vaccine candidates include cAd3-EBO-Z 
and rVSV-ZEBOV which have both proven to be protective after one single injection in NHP-studies 
and are currently in human trials (Henao-Restrepo et al. 2015, De Santis et al. 2016). rVSV-ZEBOV 
can also be used when the individual is already infected with Ebola, and an important feature which 
might be relevant for the possible use in wild apes is that oral immunization with this vaccine has 
proven possible, at least in the mouse and macaque model,  suggesting that baiting of vaccine is in 
theory possible (Qiu et al. 2009).  
Another type of vector based vaccine candidate is Cytomegalovirus based vaccine (CMV vaccine) 
(Marzi et al. 2016). In contrast to the other candidates, this vaccine is intended specifically for wild 
great apes and is designed to be able to spread from one individual to another. Ideally the vaccine 
virus should be given to relatively few individuals and subsequently spread through the population 
indefinitely whilst stimulating protection against Ebola. However, the ethics and risks of introducing 
any genetically modified virus, even if the original vector virus is naturally found in the population, 
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requires careful and thorough discussion (Tsuda et al. 2011, Murthy et al. 2013). Once released, the 
vaccine-virus can no longer be removed from the population. 
A vaccine with less safety concerns is Virus Like Particles-vaccine; it does not include any virus 
component but rather consists of a genetically engineered protein product that mimics the structure 
of EV (Marzi & Feldmann 2014). Studies in NHP, including captive chimpanzees, show that multiple 
injections are required to reach full potency of the vaccine, hence there are doubts about the use of 
this vaccine in the wild (Warfield et al. 2014). 
Additional candidates have also proven protective in NHP models and vaccine research is currently 
progressing rapidly hence further candidates and possibly additional administration routes are likely 
to appear in the future (Bukreyev & Collins 2010, Geisbert 2015).   
 
POSSIBLE VACCINATION STRATEGIES 
The different properties of the vaccines determine how they can be administered, how many 
individuals might be protected after a single intervention and how long protection lasts. The selection 
of vaccine and cost-effective vaccination strategy are therefore mainly determined by 1) the access 
to the apes, i.e. if they are habituated to human presence or not, and 2) the aim of vaccination at the 
time, i.e. to prevent introduction of Ebola from the natural source into the ape population or to stop 
the spread of infection within populations once an outbreak has started. Wild apes that have been 
habituated for behavioral research or tourism are observed on a regular basis and individual apes are 
usually identified which means that initial vaccination, monitoring and possible follow-up 
vaccination are in theory possible, whereas unhabituated apes would not be accessible for such 
treatment. The majority of apes in Africa are not habituated although for some relatively small 
populations such as the Virunga Mountain Gorillas, a relatively large proportion (ca.70%) is 
habituated (Robbins et al. 2011). It should, however, be noted that these apes, including sanctuary 
apes (Anonymous 2016b), are wild and endangered although they are habituated, and should therefore 
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not be considered guinea pigs for experimental vaccinations. For unhabituated apes, their population 
size and location, and even existence, might not be known, hence access to these apes and monitoring 
of vaccination coverage is a real challenge.  
For these reasons it is possible that different vaccines and strategies are suitable according to the 
specific population in question.  Strategies will be discussed below in general terms without referring 
to current candidates as additional candidates will likely become available (Figure 2). 
 
Prevention of Ebola spill-over into habituated populations 
The more or less constant proximity of habituated apes makes darting a possible route of vaccine 
administration. Although it can be challenging and possibly dangerous to the apes and personnel, 
darting yields a high degree of certainty that the vaccine has been received. Ideally a vaccine that 
protects after a single administration should be used to avoid excessive darting that might also have 
a negative impact on years or decades of habituation efforts. For the same reason the vaccine (with 
or without required booster) should induce long lasting protection. Although the vaccine candidates 
that are presently in human trials are considered to induce long-term protection sufficient to last for 
the duration of a human outbreak, a protection longevity of some months or even a couple of years  
might not be optimal for long term prevention of EVD in wild apes (Stanley et al. 2014, Wong et al. 
2014). 
Baiting is in theory another option for vaccine delivery to habituated apes, provided the vaccine is 
designed to induce protection after oral administration. However, apes are selective with what they 
eat hence it might be difficult to ensure that all individuals receive the vaccine or on the other hand 
that a single or few dominant individuals consume vaccine doses higher than intended (Ryan & Walsh 
2011). Furthermore, feeding wild great apes with food items that might be desirable but foreign to 
them, e.g. bananas, is not a generally accepted practice; however, the cost-benefit of such 
provisioning for vaccination purpose might have to be reconsidered. 
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As the number of habituated great apes is relatively small, it could be possible to vaccinate all or at 
least the majority of them (figure 2b), provided the costs are covered. If not, specific members that 
are important for reasons such as breeding potential and/or disease spreading capabilities within the 
social network must be selected according to the specific species and demographic structure for the 
population in question (Carne et al. 2013). It should, however, be kept in mind that as long as the 
ecology and transmission of Ebola from the natural reservoir is not determined, high-risk individuals 
within a group cannot be identified. If a safe, efficient and ethically accepted self-spreading vaccine 
should become available for use in great apes (as suggested by Marzi and collegues (2016)), such 
selection would not be necessary and relatively few individuals would require darting to induce high 
level of vaccination cover and longevity of protection in a population (figure 2d).  
 
Control of EVD outbreaks in habituated populations 
Trying to vaccinate by darting during a great ape Ebola outbreak is likely to be stressful and dangerous 
for human personnel and apes. Human safety must be addressed in planning of any intervention 
whether the ape population is habituated or not. Further, the rapid progression of disease and death 
leaves little time to vaccinate which makes it more essential to follow a logistically feasible 
vaccination priority list to prevent further spread of infection.  $µULQJYDFFLQDWLRQ¶ILJXUHFRILQ-
contact individuals and individuals in surrounding unaffected populations could be attempted 
(Henao-Restrepo et al. 2015). This approach might, however, not be fast or efficient enough to stop 
the outbreak, and virus could also possibly be introduced directly from the reservoir on the other side 
of the vaccination-borders (Leroy et al. 2004). In an outbreak situation, it would be beneficial to use 
a vaccine that is effective also when an individual is already infected. Protection induced by a 
potential self-spreading type of vaccine would require that the vaccine vector would spread and 
induce protection faster than the Ebola virus itself would spread; such a vaccine would make more 
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sense to use well before an outbreak situation but could perhaps be beneficial if used in parallel with 
other vaccinations as an extension of a ring vaccination strategy. 
An important issue is that a great ape outbreak might be accompanied by human cases. If there is low 
availability of vaccines developed for human use, one should seriously consider the cost-benefit and 
ethics of using these valuable doses on wildlife. 
 
Prevention of Ebola spill-over into non-habituated populations 
The elusive nature of non-habituated apes poses a considerable obstacle to administering injectable 
vaccines and it is questionable if vaccinating randomly encountered individuals would be sufficient 
to protect populations across Africa, especially if the vaccination would require booster injections 
after some time. The cost-benefit must be modelled for the individual populations, including factors 
such as to what proportion of the population can be expected to be reached, and the perceived risk of 
viral spill-over in the area. The unpredictable emergence of Ebola from its reservoir makes such risks 
difficult to estimate. Although relatively specific areas in North Eastern Gabon, ROC and Cote 
G¶,YRLUHKDYHSURYHQWREHHFRORJLFDOO\VXLWDEOHIRUWUDQVPLVVLRQof Ebola into great ape population, 
the majority of the tropical belt of Africa is currently considered risk area for viral emergence (Pigott 
et al. 2014, Walsh & Haseeb 2015). 
Baiting does not require close-range contact with individuals, but poses the same challenges as 
described for habituated apes and also requires efficient administration on a much larger geographical 
scale. A self-spreading vaccine that would require relatively few interventions and which could in 
theory provide widespread protection against Ebola may seem promising for remote, non-accessible 
populations but the safety and ethics of such an approach must be addressed. 
Other ideas would be to develop efficient fog sprays or environmental vaccines that can be 
administered to larger areas of remote ape habitats, or when the Ebola ecology is better understood, 
to vaccinate species that the apes could contract Ebola infection from. 
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Control of EVD outbreaks in non-habituated populations  
Firstly, outbreaks in un-monitored populations are likely to go unnoticed or to be first recognized 
when it is large enough to be detected by wildlife surveys, unless there is an efficient hunter 
surveillance network already in place. Secondly, for reasons discussed above, reaching and 
vaccinating enough unhabituated individuals in order to control a rapidly spreading outbreak is 
unlikely. Ring vaccination of unaffected habituated groups might be considered to prevent spread of 
infection to groups outside of the ring, or to protect particularly vulnerable groups within the ring.  
 
SUMMARY OF FEASABILITY AND CHALLENGES OF EFFICIENT VACCINATION OF 
WILD APES 
There are currently a number of challenges to be overcome before vaccination can be efficient from 
a conservation perspective. Nevertheless, strategies should be formulated and discussed based on up-
to-date knowledge and the prospects of future advances in vaccine development, to prepare 
financially and logistically for possibly rapid changes in vaccine availability. This needs to be done 
for each specific population to accommodate for differences in species, population size, habituation 
status, accessibility and other factors relevant to the countries in question. Management plans can be 
discussed and adjusted according to changes in the development, availability and cost of vaccines, 
disease situation, knowledge about Ebola ecology, and opinion on wildlife vaccination. To this end, 
interdisciplinary meetings including representatives from the fields of primatology, virology, wildlife 
conservation, ecology, epidemiology, virology, immunology and public health are necessary to 
discuss and find well-considered solutions for this complex topic. These discussions should also 
include how to record details of any vaccination attempt and how to monitor the effect in a scientific 
way (Travis et al. 2008). The more data that are available, the better we can implement disease models 
and adjust future disease prevention strategies. 
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NEED FOR GREAT APE HEALTH MONITORING, RESEARCH AND DISEASE 
AWARENESS 
Irrespective if future strategies for preventing Ebola will be implemented or not, monitoring of great 
ape health itself is important and should be included into conservation plans together with poaching 
control and habitat protection (Travis et al. 2006). Further, the fact that apes and humans alike are 
highly susceptible to Ebola make the great apes important sentinels for human disease, therefore 
monitoring mortality in these wildlife hosts, and collecting samples for pathogen identification, 
remains an important corner stone to predict and possibly prevent zoonotic transmission into humans 
(Calvignac-Spencer et al. 2012). It is the responsibility of any conservation and research project to 
take wildlife death seriously, to develop protocols in the event of a disease outbreak and report cases 
even if the project itself is not engaged in great ape health. This should go hand in hand with raising 
public awareness about the risk of hunting and scavenging apes, and also highlighting the importance 
of hunters and other villagers reporting dead apes, perhaps via the chiefs of the villages to the local 
health authorities. During the first bout of human outbreaks in Gabon in the nineties, lack of 
awareness of the role of great apes in Ebola outbreaks limited the epidemiological and laboratory 
investigation of these species. The need for wildlife monitoring was subsequently recognized and in 
the next series of outbreaks some years later a well prepared wildlife monitoring network was able to 
warn the health authorities about the risk of human cases and sampling of carcasses lead to the 
confirmation of  infected apes and duikers as root of the human outbreaks (Rouquet et al. 2005). 
Great ape monitoring should be done in a systematic and quantitative manner by qualified personnel, 
such as veterinarians that have been trained to perform wild animal necropsies under highly stringent 
safety conditions. Such monitoring has been shown to be a prerequisite for early detection and 
effective sampling of suspected cases (Leendertz et al. 2006, Travis et al. 2008); laboratory analysis 
is the only way to confirm Ebola infection. Antibody testing of non-invasively collected great ape 
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samples can show which population have been exposed to the virus and surveys to estimate group 
density and population numbers may inform about population declines possibly caused by Ebola 
(Cameron et al. 2016, Campbell et al. 2008, Kouakou et al. 2009, Olson et al. 2012, Reed et al. 2014). 
Identification of the virus¶ true reservoir and infection pathways in nature remains important research 
(Leendertz 2016).  This emphasizes the need for continuous funding and recruitment of people 
involved with disease monitoring, ranging from veterinarians to field primatologists, project 
managers, ecologists, and laboratory workers. We encourage the involvement of researchers and 
laboratories in great ape countries for increased sustainability of such work.  
Although not all human EVD outbreaks that have occurred can be linked to deaths in great apes, it is 
clear that contact with bush meat from any species of great ape either via hunting, scavenging or 
butchering, is a major risk factor for exposure to Ebola virus (Feldmann & Geisbert 2011, Anonymous 
2014c).  This epidemiologically and laboratory-confirmed transmission pathway should be a 
reminder that hunting animals that may be infected with EV can increase the risk of human outbreaks. 
Continuous public education by health and conservation organizations in great ape countries remains 
an important and priority task for disease prevention; a good example is the hunter surveillance and 
public health programme in Northern Congo (Anonymous 2015e).  Such outreach programmes that 
communicate, in a culturally sensitive way, the dangers of handling bushmeat enhance awareness of 
zoonotic infections from great apes and other wildlife. Although it would not affect the occurrence 
of EVD in apes, there may be indirect benefits to conservation. Possible risks of disease transmission 
between apes and humans must also be conveyed to tourists that are in relatively close contact with 
wild great apes in tourism-for-conservation- projects (Muehlenbein & Ancrenaz 2009, Macfie & 
Williamson 2010). 
 
WHAT TO DO IF EBOLA IS SUSPECTED OR CONFIRMED IN APES? 
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This review is not meant as a manual for collection and analyses of data and samples; for this we 
refer to other guidelines for great ape health monitoring (Gilardi et al. 2015). First and most important 
is to never forget that the Ebola virus is highly infectious and highly lethal and represents a major 
risk to human health; well-meaning, unskilled or unprotected investigators or tourists as well as 
highly-trained public health workers might risk their own life and possibly initiate a human outbreak. 
The rapid decomposition of carcasses in the rainforest means that finding a single carcass is very rare, 
hence encountering even one dead ape should raise awareness as this individual might be one of many 
other undetected carcasses and an immediate and intense search should be initiated. Whenever an ape 
carcass is detected, especially if Ebola is suspected, the wildlife authorities and the local ministry of 
health should be informed, following the ROC surveillance guidelines (Reed et al. 2014). Necropsy 
samples should only be sampled by specialists trained for these situations, and anybody in direct or 
indirect contact with carcasses must adhere to the highest standard of protective clothing and 
disinfection (Leendertz et al. 2006, Ringen et al. 2015).  
The possibility and limitations of vaccination in an outbreak situation, as described above, should 
ideally have been discussed well beforehand and a network of assistance for such emergency 
situations should be established. Finally, openly sharing experiences after an outbreak is crucial for 
improving preparedness for future outbreaks. 
 
CONCLUSION 
Ebola Viruses can cause large epidemics in humans and great apes. The likelihood that these viruses 
will continue to emerge unpredictably in tropical Africa highlights the necessity to protect apes from 
the severe impact of EVD and to reduce human contact to infected wildlife sources. Further research 
is required to determine the natural circulation of EVs and the mechanisms facilitating viral 
emergence; however, bushmeat from infected apes is confirmed as source of infection for human 
outbreaks hence public education of zoonotic diseases and monitoring of great ape health remain 
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important human outbreak prevention strategies. With the rapid progress in Ebola vaccine 
development, vaccination of wild great apes might become a tool for conservation and protection of 
human health in the future. Research must focus on developing safe and efficient safe vaccines that 
can be delivered efficiently to larger populations of elusive wild apes in their natural remote habitats.  
A thorough understanding of the disease anGWKHJUHDWDSHV¶QDWXUDOEHKDYLRUDVZHOODVNQRZOHGJH
of the properties of vaccine candidates is necessary to assess the feasibility of potential vaccination 
programs. This article describes the occurrence of EVD in great apes and discusses the possibilities 
and limitations of vaccinating wild great apes against Ebola. 
 
 ACKNOWLEDGEMENTS 
This study was commissioned and funded by the United Nations Environmental Programme Great 
Apes Survival Partnership (GRASP). We thank Charles Emil for the assistance with the figures. 
Special thanks to Laura Darby and Nicolien de Lange for their assistance in editing the manuscript.  
 
REFERENCES 
Anonymous (2014a) State of the Apes: Extractive Industries and Ape Conservation. Cambridge 
University Press, Cambridge, United Kingdom. 
 
Anonymous (2014b) Regional Action Plan for the Conservation of Western Lowland Gorillas and 
Central Chimpanzees 2015±2025. IUCN, Gland, Switzerland. 
 
Anonymous (2014c) An update on the risk of transmission of Ebola virus (EBOV) via the food 
chain. European Food Safety Authority Journal 12, 25.  
 
Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder, Mary K. and Humle, 
Tatyana and Leendertz, Fabian H. (2016) Ebola in great apes ± current knowledge, possibilities for vaccination, and 





Anonymous (2015a) Centre for Disease Control and Prevention. Outbreaks chronology: Ebola 
Virus Disease. http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html.  
 
Anonymous (2015b) World Health Organisation Ebola virus diseasefactsheet. 
http://www.who.int/mediacentre/factsheets/fs103/en/. 
 




Anonymous (2015d) World Health Organisation. Manual for the care and management of patients 
in Ebola Care Units/ Community Care Centres. 
http://apps.who.int/iris/bitstream/10665/149781/1/WHO_EVD_Manual_ECU_15.1_eng.pdf?ua=1. 
 
 Anonymous (2015e) Wildlife Conservation Society. http://www.wcs.org/conservation-
challenges/wildlife-health/disease-investigations/ebola.aspx. 
 
Anonymous (2016a) The IUCN Red List of Threatened Species. http://www.iucnredlist.org/. 
 
Anonymous (2016b) Pan African Sanctuaries Alliance http://www.pasaprimates.org 
 
Bermejo M (2004) Home-range use and intergroup encounters in western gorillas (Gorilla g. 
gorilla) at Lossi forest, North Congo. American Journal of Primatology 64:223-232.  
 
Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder, Mary K. and Humle, 
Tatyana and Leendertz, Fabian H. (2016) Ebola in great apes ± current knowledge, possibilities for vaccination, and 





Bermejo M, Rodriguez-Teijeiro J D, Illera G, Barroso A, Vila C,  Walsh PD (2006) Ebola outbreak 
killed 5000 gorillas. Science 314:1564.  
 
Boesch C, Boesch-Achermann H (2000) The Chimpanzees of the Taï Forest: Behavioural Ecology 
and Evolution. Oxford University Press, Oxford, United Kingdom. 
 
Bradley BJ, Doran-Sheehy D M, Lukas D, Boesch C,  Vigilant L (2004) Dispersed male networks 
in western gorillas. Current Biology 14:510-513.  
 
Bukreyev A,  Collins PL (2010) Filovirus vaccines: what challenges are left? Expert Review of 
Vaccines 9:5-8.  
 
Caillaud D, Levrero F, Cristescu R, Gatti S, Dewas M, Douadi M et al. (2006) Gorilla susceptibility 
to Ebola virus: the cost of sociality. Current Biology 16:489-491.  
 
Calvignac-Spencer S, Leendertz SA, GillespieTR, Leendertz FH (2012) Wild great apes as sentinels 
and sources of infectious disease. Clinical Microbiology and Infection 18: 521-527.  
 
Cameron KN, Reed P, Morgan DB, Ondzie AI, Sanz CM, Kühl HS, Olson SH, Leroy E, Karesh 
WB, Mundry R (2016) Spatial and Temporal Dynamics of  mortality event among Central African 
Great Apes. PLOS One 11(5): e0154505 
 
Campbell G, Kuehl H, N'Goran K , Boesch C (2008) Alarming decline of West African 
chimpanzees in Cote d'Ivoire. Current  Biology 18:903-904. 
 
Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder, Mary K. and Humle, 
Tatyana and Leendertz, Fabian H. (2016) Ebola in great apes ± current knowledge, possibilities for vaccination, and 





Carne C, Semple S, Morrogh-Bernard H, Zuberbühler K, Lehmann J (2013) Predicting the 
Vulnerability of Great Apes to Disease: The Role of Superspreaders and Their Potential 
Vaccination. PLOS One 8:e84642 
 
Chughtai AA, Barnes M, Macintyre CR (2016) Persistence of Ebola virus in various body fluids 
during convalescence: evidence and implications for disease transmission and control. 
Epidemiology and Infection 25:1-9.  
 
Cohen J, Kupferschmidt K (2014) Infectious Diseases. Ebola vaccine trials raise ethical issues. 
Science 346:289-290.  
 
De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G et al. (2016) 
Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a 
randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infectious 
Disease 16:311-320.  
 
Falzarano D (2016) Ebola vaccines: we have options. Lancet Infectious Disease 16:267-268.  
 
Fedigan LM (2010) Ethical issues faced by field primatologists: asking the relevant questions. 
American Journal of Primatology 72:754-771.  
 
Feldmann H, Geisbert TW (2011) Ebola haemorrhagic fever. The Lancet 377:849-862. 
 
Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder, Mary K. and Humle, 
Tatyana and Leendertz, Fabian H. (2016) Ebola in great apes ± current knowledge, possibilities for vaccination, and 





Formenty P, Boesch C, Wyers M, Steiner C, Donati F, Dind F et al. (1999) Ebola virus outbreak 
among wild chimpanzees living in a rain forest of Cote d'Ivoire. Journal of Infectious Diseases 
179:120-126.  
 
Geisbert TW (2015) Emergency treatment for exposure to Ebola virus: the need to fast-track 
promising vaccines. Journal of the american Medical Association 313:1221-1222.  
 
Geisbert TW, Geisbert J B, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A et al. (2009) 
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three 
species of ebola virus. Journal of Virology 83:7296-7304.  
 
Genton C, Cristescu R, Gatti S, Levrero F, Bigot E, Caillaud D et al. (2012) Recovery potential of a 
western lowland gorilla population following a major Ebola outbreak: results from a ten year study. 
PLoS One 5: e37106.  
 
Genton C, Pierre A, Cristescu R, Levrero F, Gatti S, Pierre JS et al. (2014) How Ebola impacts 
social dynamics in gorillas: a multistate modelling approach. Journal of  Animal Ecolology 84:166-
76. 
 
Georges AJ, Leroy E M, Renaut AA, Benissan CT, Nabias RJ, Ngoc MT et al. (1999) Ebola 
hemorrhagic fever outbreaks in Gabon, 1994-1997: epidemiologic and health control issues. 
Journal of Infectious Disease 179:65-75.  
 
Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder, Mary K. and Humle, 
Tatyana and Leendertz, Fabian H. (2016) Ebola in great apes ± current knowledge, possibilities for vaccination, and 





Gilardi KV, Gillespie TR, Leendertz, FH, Macfie EJ, Travis DA, Whittier CA, Williamson EA 
(2015) Best Practice Guidelines for Health Monitoring and Disease Control in Great Ape 
Populations. ICUN SSC Primate Specialist Group, Gland, Switzerland. 
 
Goodall J (1986) The chimpanzees of Gombe: Patterns of behaviour.  Harvard University Press, 
Cambridge, United Kingdom. 
 
Gruen L, Fultz A, Pruetz J (2013) Ethical issues in African great ape field studies. Institute for 
Laboratory Animal Research Journal 54:24-32.  
 
Hastings BE, Kenny D, Lowenstine LJ, and Foster JW (1991) Mountain gorillas and measles: 
ontogeny of a wildlife vaccination program. Proceedings of American Association of Zoo 
Veterinarians 198-205. 
 
Haurez B, Petre CA, Doucet JL (2013) Impacts of logging and hunting on western lowland gorilla 
(Gorilla gorilla gorilla) populations and consequences for forest regeneration. A review. 
Biotechnologie, Agronomie, Société et Environnement  17:364-372. 
 
Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A et al. (2015) 
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: 
interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386:857-866.  
 
Hockings KJ, McLennan MR, Carvalho S, AncrenazM, Bobe R, Byrne RW et al. (2015) Apes in 
the Anthropocene: flexibility and survival. Trends in Ecology and Evolution 30:215-222.  
 
Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder, Mary K. and Humle, 
Tatyana and Leendertz, Fabian H. (2016) Ebola in great apes ± current knowledge, possibilities for vaccination, and 





Hopkin M (2007) Gorillas on the list. Nature 449:127.  
 
Huijbregts B, Wachter PD, Ndong Obiang LS,  Akou ME (2003) Ebola and the decline of gorilla 
(Gorilla gorilla) and chimpanzee (Pan troglodytes) populations in Minkebe Forest, north-eastern 
Gabon. Oryx 37:437±443. 
 
Karesh W,  Reed P (2005) Ebola and great apes in Central Africa: current status and future needs. 
Bulletin de la Société de pathologie exotique 98:237-238. 
 
Karesh WB, Dobson A, Lloyd-Smith JO, Lubroth J, Dixon MA, Bennett M et al. (2012) Ecology of 
zoonoses: natural and unnatural histories. Lancet 380:1936-1945.  
 
Kondgen S, Kuhl H, N'Goran PK, Walsh PD, Schenk S, Ernst N et al. (2008) Pandemic human 
viruses cause decline of endangered great apes. Current Biology 18:260-264.  
 
Kouakou CY, Boesch C,  Kuehl H (2009) Estimating chimpanzee population size with nest counts: 
validating methods in Tai National Park. American Journal of Primatology 71:447-457.  
 
Kuhn JH (2008) Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory 
studies. Archives of Virology Supplement 20:13-360. 
 
Kuhn  JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y et al. (2010) Proposal for a 
revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus 
abbreviations.  Archives of Virology 155:2083-2103. 
 
Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder, Mary K. and Humle, 
Tatyana and Leendertz, Fabian H. (2016) Ebola in great apes ± current knowledge, possibilities for vaccination, and 





Lahm SA, Kombila M, Swanepoel R,  Barnes RF (2007) Morbidity and mortality of wild animals in 
relation to outbreaks of Ebola haemorrhagic fever in Gabon, 1994-2003. Transactions of the Royal 
Society of Tropical Medicine and Hygiene 101:64-78.  
 
Laurance WF, Goosem M, Laurance SGW (2009) Impacts of roads and linear clearings on tropical 
forests. Trends in Ecology and Evolution 24:659-669. 
 
Lee BY, Moss WJ, Privor-Dumm L, Constenla DO, Knoll MD,  O'Brien KL (2015) Is the world 
ready for an Ebola vaccine? Lancet 385:203-204.  
 
Leendertz FH, Pauli G, Maetz-Rensing K, Boardman W, Nunn C, Ellerbrok H, Jensen SA, Junglen 
S, Boesch C (2006) Pathogens as drivers of population declines: The importance of systematic 
monitoring in great apes and other threatened mammals.  Biological Concervation 131:325-337. 
 
Leendertz SAJ (2016) Testing new hypotheses regarding Ebolavirus reservoirs. Viruses 8(2) 
 
Leendertz SA, Gogarten JF, Düx A, Calvignac-Spencer S, Leendertz F (2016) Assessing the 
evidence of fruit bats as the reservoir for Ebola viruses. Ecohealth 13:18-25. 
 
Lehmann J, Boesch C (2004) To fission or to fusion: effects of community size on wild chimpanzee 
(Pan troglodytes verus) social organisation. Behavioural Ecology & Sociobiology 56:207-216 
 
Leroy EM, Rouquet P, Formenty P, Souquiere, S, Kilbourne A, Froment JM et al. (2004) Multiple 
Ebola virus transmission events and rapid decline of central African wildlife. Science 303:387-390.  
 
Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder, Mary K. and Humle, 
Tatyana and Leendertz, Fabian H. (2016) Ebola in great apes ± current knowledge, possibilities for vaccination, and 





Leroy EM, Telfer P, Kumulungui B, Yaba P, Rouquet P, Roques P et al. (2004) A serological 
survey of Ebola virus infection in central African nonhuman primates. Journal of Infectious 
Diseases 190:1895-1899.  
 
Macfie EJ, Williamson EA (2010) Best practice guidelines for great ape tourism. IUCN/SSC 
Primate Specialist Group, Gland, Switzerland. 
 
Maganga GD, Kapetshi J, Berthet N, Ilunga BK, Kingebeni PM et al. (2014) Ebola Virus Disease in 
the Democratic Republic of Congo. New England Journal of Medicine 371:2083-91 
 
Maisels F, Ella Akou M, Douckaga M, Moundounga A (2004) Mwagne National Park, Gabon: 
large mammals & human impact. WCS/ WWF, Gabon. 
 
Mari Saez A, Weiss S, Nowak K, Lapeyre V, Zimmermann F, Dux A et al. (2014) Investigating the 
zoonotic origin of the West African Ebola epidemic. EMBO Molecular Medicine 7:17-23.  
 
Marzi A,  Feldmann H (2014) Ebola virus vaccines: an overview of current approaches. Expert 
Review of Vaccines 13:521-531.  
 
Marzi A, Murphy AA, Feldmann H, Parkins CJ, Haddock E, Hanley PW et al. (2016) 
Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates 
from Ebola virus infection. Scientific Reports 6:21674.  
 
Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder, Mary K. and Humle, 
Tatyana and Leendertz, Fabian H. (2016) Ebola in great apes ± current knowledge, possibilities for vaccination, and 





Morgan D, Sanz C (2007) Best practive guidelines for reducing the impact of commercial logging 
on great apes in Western Equatorial Africa. ICUN SSC Primate Specialist Group, Gland, 
Switzerland. 
 
Muehlenbein MP, Ancrenaz M (2009) Minimizing pathogen transmission at primate ecotourism 
destinations : the need for input from travel medecine.  Journal of Travel Medicine 16:229-232. 
 
Murthy S, Couacy-Hymann E, Metzger S, Nowak K, De Nys H, Boesch C et al. (2013) Absence of 
frequent herpesvirus transmission in a nonhuman primate predator-prey system in the wild. Journal 
of Virology 87:10651-10659.  
 
N'Goran PK, Boesch C, Mundry R, N'Goran EK, Herbinger I, Yapi F A et al. (2012) Hunting, law 
enforcement, and African primate conservation. Conservation Biology 26:565-571. 
  
Nishida T, Zamma K, Matsusaka T,  Inaba A (2010) Chimpanzee Behavior in the Wild. Springer, 
Tokyo, Japan. 
 
Nkoghe D, Kone ML, Yada A, Leroy E (2011) A limited outbreak of Ebola haemorrhagic fever in 
Etoumbi, Republic of Congo, 2005. Transactions of the Royal Society of Tropical Medicine and 
Hygiene 105:466-472.  
 
Olival KJ, Hayman DT (2014) Filoviruses in bats: current knowledge and future directions. Viruses 
6:1759-1788.  
 
Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder, Mary K. and Humle, 
Tatyana and Leendertz, Fabian H. (2016) Ebola in great apes ± current knowledge, possibilities for vaccination, and 





Olson SH, Reed P, Cameron KN, Ssebide BJ, Johnson CK, Morse SS et al. (2012) Dead or alive: 
animal sampling during Ebola hemorrhagic fever outbreaks in humans. Emerging Health Threats 
Journal 
 5.  
 
Olson SH, Reed P, Ondzie A, Cameron K, Joly D (2012) Maximizing nonhuman primate fecal 
sampling in the Republic of Congo. Journal Of Wildlife Diseases 48:888-898 
 
Pigott DM, Golding N, Mylne A, Huang Z, Henry AJ, Weiss DJ et al.(2014) Mapping the zoonotic 
niche of Ebola virus disease in Africa. Elife, 3.  
 
Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, Dick D et al. (2009) Mucosal 
immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong 
ebola GP-specific immune responses. PLoS One, 4:e5547.  
 
Rabinowitz PM, Kock R, Kachani M, Kunkel R, Thomas J, Gilbert J et al. (2013) Toward proof of 
concept of a one health approach to disease prediction and control. Emerging Infectious 
Diseases19:doi:10.3201 
  
Reed PE, Mulangu S, Cameron KN, Ondzie AU, Joly D, Bermejo M et al. (2014) A new approach 
for monitoring ebolavirus in wild great apes. PLoS Neglected Tropical Diseases 8: e3143. 
  
Ringen K, Landrigan PJ, Duffy R, Melius J, McDiarmid MA (2015) Occupational safety and health 
protections against Ebola virus disease. American Journal of Industrial Medicine 58:703-14 
 
Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder, Mary K. and Humle, 
Tatyana and Leendertz, Fabian H. (2016) Ebola in great apes ± current knowledge, possibilities for vaccination, and 





Robbins MM, Gray M, Fawcett KA, Nutter FB, Uwingeli P, Mburanumwe I et al. (2011) Extreme 
conservation leads to recovery of the Virunga mountain gorillas. PLoS One 6:e19788.  
 
Rougeron V, Feldmann H, Grard G, Becker S, Leroy EM (2015) Ebola and Marburg haemorrhagic 
fever. Journal of Clinical Virology 64:111-119.  
 
Rouquet P, Froment JM, Bermejo M, Kilbourn A, Karesh W, Reed P et al. (2005) Wild animal 
mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001-2003. 
Emerging Infectious Diseases 11:283-290.  
 
Ryan SJ, Jones JH, Dobson AP (2013) Interactions between social structure, demography, and 
transmission determine disease persistence in primates. PLoS One 8:e76863.  
 
Ryan SJ, Walsh, PD (2011) Consequences of non-intervention for infectious disease in African 
great apes. PLoS One 6:e29030.  
 
Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC et al. (2014) 
Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus 
challenge. Nature Medicine 20:1126-9  
 
Towner JS, Sealy TK, Khristova ML, Albarino CG, Conlan S, Reeder SA et al. (2008) Newly 
discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathogen 
4:e1000212. 
  
Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder, Mary K. and Humle, 
Tatyana and Leendertz, Fabian H. (2016) Ebola in great apes ± current knowledge, possibilities for vaccination, and 





Travis DA, Hungerford L, Engel GA, Jones-Engel L (2006) Disease risk analysis: a tool for primate 
conservation planning and decision making. American Journal of Primatology 68:855-867.  
 
Travis DA, Lonsdorf EV, Mlengeya T,  Raphael J (2008) A science-based approach to managing 
disease risks for ape conservation. American Journal of Primatology 70:745-750.  
 
Tsuda Y, Caposio P, Parkins CJ, Botto S, Messaoudi I, Cicin-Sain L, et al. (2011) A replicating 
cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers 
protection against Ebola virus. PLoS Neglected Tropical Diseases 5:e1275.  
 
Viana M, Mancy R, Biek R, Cleaveland S, Cross PC, Lloyd-Smith JO et al. (2014) Assembling 
evidence for identifying reservoirs of infection. Trends in Ecology and Evolution 29:270-279.  
 
Vigilant L, Hofreiter M, Siedel H, Boesch C (2001) Paternity and relatedness in wild chimpanzee 
communities. Proceedings of the National Acadademy of Sciences of the United States of America, 
98:12890-12895.  
 
Vogel G (2006) Ecology. Tracking Ebola's deadly march among wild apes. Science 314:1522-1523.  
 
Waldman L (2015) Urbanisation, the Peri-urban growth and Zoonotic disease. Institute of 
developmental Studies Practice Paper in Brief 22. 
 
Walsh PD, Tutin CEG, Oates, JF, Baillie JEM, Maisels F, Stokes EJ et al. (2007) IUCN Red List of 
Threatened Species. http://www.iucnredlist.org/details/9404/0  
 
Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder, Mary K. and Humle, 
Tatyana and Leendertz, Fabian H. (2016) Ebola in great apes ± current knowledge, possibilities for vaccination, and 





Walsh PD, Bermejo M,  Rodriguez-Teijeiro JD (2009) Disease avoidance and the evolution of 
primate social connectivity: Ebola, bats, gorillas, and chimpanzees. In Huffman MA & Chapman 
CA (eds) Primate Parasite Ecology: The Dynamics and Study of Host-Parasite Relationships, 183-
198. Cambridge University Press, Cambridge, United Kingdom. 
 
Walsh PD, Breuer T, Sanz C, Morgan D, Doran-Sheehy D (2007) Potential for Ebola transmission 
between gorilla and chimpanzee social groups. The American Naturalist 169:684-689.  
 
Walsh MG, Haseeb MA (2015) The landscape configuration of zoonotic transmission of Ebola 
virus disease in West and Central Africa: interaction between population density and vegetation 
cover Peer J 3:e735 
 
Warfield KL, Goetzmann, JE, Biggins JE, Kasda MB, Unfer RC, Vu H et al. (2014) Vaccinating 
captive chimpanzees to save wild chimpanzees. Proceedings of the National Acadademy of 
Sciences of the United States of America 111:8873-8876.  
 
Warren Y,  Williamson EA (2004) Transport of dead infant mountain gorillas by mothers and 
unrelated females. Zoo Biology 23:375-378. 
 
Wittmann TJ, Biek R, Hassanin A, Rouquet P, Reed P, Yaba P et al. (2007) Isolates of Zaire 
ebolavirus from wild apes reveal genetic lineage and recombinants. Proceedings of the National 
Acadademy of Sciences of the United States of America 104:17123-17127.  
 
Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder, Mary K. and Humle, 
Tatyana and Leendertz, Fabian H. (2016) Ebola in great apes ± current knowledge, possibilities for vaccination, and 





Wong G, Audet J, Fernando L, Fausther-Bovendo H, Alimonti J B, Kobinger GP et al. (2014) 
Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides 










Leendertz, Siv Aina J. and Wich, Serge A. and Ancrenaz, Marc and Bergl, Richard A. and Gonder, Mary K. and Humle, 
Tatyana and Leendertz, Fabian H. (2016) Ebola in great apes ± current knowledge, possibilities for vaccination, and 







Figure 1. Overview of Ebola-positive great ape carcasses and points of origin of human 
outbreaks across the tropical belt of Africa. The larger green areas in Gabon and ROC represent 
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Figure 2. Schematic presentation of the principles of Ebola vaccination strategies in great apes   
A- vaccination border for prevention of spillover from natural reservoir or other hosts; B-vaccination 
of specific groups, i.e. habituated groups; C-ring vaccination in the event of an EVD outbreak; D- the 
principle of a self-spreading vaccine. The bats represent any possible source of Ebola infection. The 
open dots and circles on the grey background illustrate individuals and groups in the ape population. 
Black dots are Ebola infected apes; red dots are vaccinated apes. 
Red arrows indicate introduction of vector virus, the orange dots and arrows shows subsequent 
spread, white arrows indicate route of even further spread. 
 
